Share

April 18, 2017; 88 (16) ArticleOpen Access

Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease

Lynn Rochester, Brook Galna, Sue Lord, Alison J. Yarnall, Rosie Morris, Gordon Duncan, Tien K. Khoo, Brit Mollenhauer, David J. Burn
First published March 22, 2017, DOI: https://doi.org/10.1212/WNL.0000000000003840
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
884

Share

This article has a correction. Please see:

Abstract

Objective: This prospective observational study investigates the role of CSF biomarkers in predicting progression of dopa-resistant gait impairments in Parkinson disease (PD) in the first 36 months from diagnosis.

Methods: Quantitative gait analysis was carried out longitudinally using an instrumented walkway (GAITRite) in 108 people with PD and 130 age-matched controls. A subgroup of 44 people with PD underwent lumbar puncture from which a battery of CSF biomarkers was measured: β-amyloid 1–42 and 1–40 (Aβ42 and Aβ40), total and phosphorylated tau protein (t-tau/p-tau181), and α-synuclein (αSyn). Linear mixed models examined the association between CSF and dopa-resistant gait characteristics (defined as substantial progression despite optimal medication).

Results: Low baseline CSF Aβ42, and to a lesser extend Aβ40, predicted decline in gait characteristics in the first 3 years following diagnosis, independently explaining up to 12% of progression of step time variability (single task) and step length variability (dual-task). Interestingly, these findings were independent of age and cognition.

Conclusions: These findings implicate underlying amyloid pathology in neural networks involved in locomotor control. Results suggest that disturbed Aβ metabolism may be a biomarker for dopa-resistant gait impairments in early PD. Our findings raise interesting questions regarding therapeutic interventions such as compounds or molecules aimed at reducing amyloid burden to mitigate gait disturbance in early PD and potentially falls risk. Finally, progression of discrete gait characteristics suggests they may have potential as clinical biomarkers of pathology and disease progression.

GLOSSARY

αSyn=
α-synuclein;
Aβ=
β-amyloid;
ICICLE=
Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation;
LEDD=
levodopa equivalent dose;
LP=
lumbar puncture;
MoCA=
Montreal Cognitive Assessment;
PD=
Parkinson disease;
PIGD=
postural instability and gait

Parkinson disease (PD) is a common neurodegenerative disorder, second to Alzheimer disease.1 Gait impairments are significant in very early disease, and even at this stage dominate as risk factors for falls.2 While some aspects of gait are well-controlled by dopaminergic therapies in the early stages, resistance to levodopa makes clinical management challenging.

Recent work highlights the significant contribution of cholinergic disturbance to gait,3,4 and recent trials targeting the cholinergic system have met with moderate success.5 CSF proteins (e.g., β-amyloid [Aβ] 40 and Aβ42; total and p-tau181), traditionally biomarkers of dementia and dementia risk,6,–,9 have also been implicated in motor impairment, highlighting a role for pathologic protein accumulation other than Lewy body and PD-specific α-synuclein (αSyn). Cross-sectional studies in early and advanced PD show an association between CSF biomarkers and postural instability and gait (PIGD) phenotype.10,11 However, lack of quantitative gait analysis in these studies limits interpretation of findings. More importantly, longitudinal studies are lacking and urgently required in order to establish prediction.

The aims of this study were to investigate the role of CSF biomarkers to predict progression of dopa-resistant gait impairments in the first 36 months from diagnosis in PD. We were interested in the mechanisms underpinning dopa-resistant gait progression to provide an essential platform for future therapeutic interventions to mitigate gait disturbance and potential falls risk. Based on previous cross-sectional literature, we hypothesized that Aβ42 and p-tau181 would predict progression in dopa-resistant gait characteristics.

METHODS

Participants.

Participants were recruited into Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation (ICICLE)–GAIT a median of 5 months from diagnosis. This is a nested study within ICICLE-PD, an incident cohort study conducted between June 2009 and December 2011. A subset of the cohort was recruited into ICICLE-Gait at the same time (figure 1). Controls of a similar age and sex were recruited from community sources. The methods have been described in full in previous publications,12,–,14 and are included as supplemental material at Neurology.org. Participants were tested “on” medication, which was defined as 1 hour after PD medication. Participants were evaluated at the Clinical Ageing Research Unit, Newcastle University, UK.

Figure 1
Figure 1 Participant flowchart

Flowchart of participants recruited and assessed as part of the ICICLE-Gait study.

Standard protocol approvals, registrations, and patient consents.

The study was approved by the Newcastle and North Tyneside research and ethics committee and all participants gave informed consent.

Demographic and clinical measures.

Clinical assessments included a standardized neurologic examination and the Movement Disorder Society–revised Unified Parkinson's Disease Rating Scale,15 from which Hoehn & Yahr stage16 and motor phenotype were calculated.17 Levodopa equivalent dose (LEDD) scores were calculated according to established methods.18 Global cognition was assessed using Montreal Cognitive Assessment (MoCA).19

Quantitative gait analysis and gait characteristics.

Gait was assessed using a 7 meters long × 0.6 meters wide instrumented walkway (Platinum model GAITRite, software version 4.5, CIR Systems, Franklin, NJ). Participants were instructed to walk at their comfortable walking pace for 2 minutes around a 25-meter oval circuit under single and dual-task conditions. The dual-task protocol involved walking and memorizing digits, based on the Wechsler Forward Digit Span, which was used as the concurrent cognitive task.20,21 Gait was repeatedly sampled as participants walked over the GAITRite mat (included in the 25-meter circuit) for a minimum of 5 passes (>40 steps per participant).22 Gait was quantified according to an a priori model developed for older adults23 and validated in PD24 that describes 16 discrete gait characteristics.25 We examined change in each gait characteristic over 36 months and characteristics that exhibited substantial change (despite optimal medication) were defined as dopa-resistant. Figure e-1 provides further details of the acquisition and processing of the gait data.

Quantification of CSF biomarkers.

CSF biomarkers were measured using a robust protocol.13 Lumbar puncture (LP) was performed on a subset of consenting participants using a standardized method as detailed previously.13 All LPs were done between 8 and 10 am after an overnight fast and while withholding PD medications. Samples were centrifuged within 15 minutes of collection at 2,000 g at 4°C for 10 minutes. The supernatant was divided into aliquots and frozen at −80°C, then analyzed for Aβ42 and Aβ40 using commercially available assays: Aβ42: Innotest TH β-amyloid (1–42), Fujirebio Inc./Innogenetics, Gent, Belgium; total and p-tau and Aβ40: hAmyloid β40, ELISA Aβ GmbH, Heidelberg, Germany.12,13,26,27 Samples with artificial blood contamination (as assessed by visual inspection during LP, erythrocyte count >50/μL3, or semiquantitative analysis of hemoglobin [using Hemastix, Siemens Healthcare Diagnostics GmbH, Eschborn, Germany]) were excluded from analysis. No samples were excluded in the current analysis.

Statistical analysis.

CSF biomarkers were selected for analysis on the basis of previous reports.10,11 Dopa-resistant gait impairments were identified as follows: first, change per year for all (16) gait characteristics derived from single and dual task testing was assessed with a linear mixed-effects model (lme4 package, R statistical software version 3.2.2, Vienna, Austria).28,29 Participants and time (from baseline assessment to subsequent testing sessions) were included as random effects and age at baseline and sex as fixed effects. We then examined between-group change in gait with group (control, PD) as a fixed effect. Rate of progression was determined in the total cohort (n = 108 PD and 130 controls) over 36 months (repeat assessments every 18 months from diagnosis) and then extracted for each individual for further analysis. Finally, bivariate correlations between change in LEDD and change in gait over 36 months for all CSF markers were conducted (data not shown), with significant relationships revealing dopa-resistant gait characteristics. These 3 steps validated the dopa-resistant classification; namely, substantial progression of gait impairment despite optimal medication; progression greater than controls; and no association between change in LEDD and gait over 36 months.

The second stage of analysis established whether CSF markers could predict progression in dopa-resistant gait characteristics using general linear modeling and controlling for age, global cognition (MoCA), and baseline gait. Preliminary data analysis suggested a potential interaction between baseline gait and CSF markers in predicting gait progression, and models were examined with and without this interaction. Baseline gait was dichotomized around the group median (to ensure balanced groups) for each variable.

Linearity of progression, normality, and homoscedasticity were inspected to ensure robustness of the fitted mixed and general linear models. There was moderate positive skewness in gait decline for step length and step time variability. Rerunning the models with log transformations did not affect findings; therefore the final models are presented using untransformed data to aid interpretation. A threshold of p < 0.05 was used to inform interpretation and 2-tailed 95% confidence intervals were calculated as interval estimates for rate of progression of gait impairment and its predictors in the general linear model.

RESULTS

Participant characteristics.

Demographic and clinical data are shown in table 1. Of the 158 participants recruited to ICICLE-PD, 56 consented to LP and of these, 47 also consented to ICICLE-Gait. Participants without longitudinal assessment at each time point were excluded, leaving 44 participants for analysis. Participants were a median of 5 months postdiagnosis at baseline and 41 months at the 36-month follow-up assessment. They had mild disease with little difference between the subgroup who underwent CSF examination and the total PD cohort. There were no differences in global cognitive scores between the subgroup and total group of participants with PD. The UPDRS-III scores, PIGD phenotype, and mean LEDD dose were lower than the entire group, indicating less severe disease.

View this table:
Table 1

Baseline demographic and clinical characteristics of participants included in longitudinal gait analysis

Gait progression in early PD.

Gait outcomes were stable over 36 months for controls. For participants with PD, dopa-resistant gait characteristics (and % yearly progression rate) under single task conditions included variability of step time (4.5% per year), step length (5.7% per year), and step width (3.4% per year), and under dual-task conditions, variability of step length (5.7% per year) (table 2 for descriptive data and change depicted in absolute values). Progression of gait impairment was defined by an increase in variability (expressed as the SD). Increased dosage of levodopa (LEDD) over the 36 months was not related to progression of variability of step time (single-task r = 0.015, p = 0.877), or step length (single-task r = −0.039, p = 0.687; dual-task r = 0.155, p = 0.108), corroborating that these variables represented dopa-resistant progression. However, an increase in levodopa dosage was related to an increase in single-task step width variability (r = 0.218, p = 0.023), and was therefore not included in subsequent analysis.

View this table:
Table 2

Baseline and change (∆) of gait per year in 130 control participants and 108 people with Parkinson disease (PD)

Table 3 and figure 2 describe the relationship between baseline CSF and change in gait. Low baseline Aβ42 was an independent predictor of progression of step time variability (single task) in people with high baseline step time variability (above median: >16.7 ms). The overall model accounted for 48.5% of variance in progression of step time variability with Aβ42 independently accounting for 12.0%, independent of age and global cognition, which were not significant predictors. Aβ42 predicted progression of step length variability (dual-task) independent of baseline gait values, explaining 26.6% of the overall model variance and Aβ42 independently explaining 9.8%. Age and global cognition were not significant predictors in the model. In addition, we found that Aβ40 was a significant predictor of progression of step length variability (dual-task), with the full model explaining 22% of variance and Aβ40 alone explaining 11.1%. A significant interaction indicated a low baseline Aβ40 predicted progression in step length variability in participants with a high baseline step length variability (above median: >2.36 × 10−2 meters). There were no associations with total and p-tau181, Aβ40/42, or αSyn.

View this table:
Table 3

General linear models to predict change in gait using CSF (n = 44) of people with Parkinson disease

Figure 2
Figure 2 Correlation between baseline CSF and change in gait

Relationship between baseline CSF markers and change in gait in people with Parkinson disease.

Because previous reports highlight a relationship with motor phenotype (PIGD), we carried out additional analysis to see if PIGD phenotype predicted gait progression. While we saw a relationship at baseline, additional analysis of variance showed that gait progression did not differ between PIGD and TD motor phenotypes (p = 0.407).

DISCUSSION

We report a study exploring the role of CSF biomarkers in the progression of gait impairment in early PD. We prioritized dopa-resistant gait characteristics because of the need to understand mechanisms explaining progression and identify potential therapeutic targets. Low baseline CSF Aβ42, and to a lesser extent Aβ40, predicted decline in gait characteristics in the first 3 years following diagnosis. The nature of the findings suggests a role for amyloid pathology. Our study included longitudinal evaluation in very early PD, the use of a robust model to inform (a priori) the selection of gait characteristics, and a broad battery of CSF proteins. The study was carried out in a community-based prospective incident cohort with robust case ascertainment and thus generalizes to idiopathic PD. Our findings are important for 2 key reasons. First, they point to potential mechanisms and novel targets for intervention to mitigate dopa-resistant gait disturbance (and by implication fall risk) at a very early stage of PD, and second, they identify discrete gait characteristics as potential clinical biomarkers for disease progression and therapeutic response.

Two previous studies have explored the relationship between CSF proteins and motor features, classified by motor phenotype. Lower values of Aβ42 and to a lesser extent Aβ40 were predictors independently explaining up to 12% of the variance in progression of dopa-resistant gait characteristics compared with CSF total and p-tau181, Aβ40/42, and αSyn, which were not associated with gait progression. Our findings broadly concur with previous cross-sectional reports showing a relationship with amyloid (from CSF and PET imaging) and motor disturbance especially in the PIGD phenotype in early and advanced PD.10,11,30 However, importantly, our findings highlight limitations of previous work and argue for a more selective investigation of gait impairment.

We found that motor phenotype is not a proxy for dopa-resistant gait impairments as it is not specific to dopa-resistant features or their progression, highlighting the limitations of cross-sectional study design and the use of motor phenotype. This is most likely explained by recent work that shows motor phenotype is unstable in early disease and individuals transition between phenotypes, questioning its longitudinal utility.31 This study provides evidence implicating amyloid in the pathogenesis of dopa-resistant gait characteristics in early PD, although direct causality is unknown.

Our findings highlight a possible role for disturbed amyloid metabolism in the neural networks involved in gait control. A number of explanations are possible to explain the mechanisms by which disturbed amyloid metabolism may exert an influence on gait. Lower values of Aβ42 and Aβ40 are generally considered to correlate with plaque formation in the brain.7,32 Aβ plaque formation may exert a direct effect on synaptic function in the absence of tau33 influencing the neural circuitry subserving dopa-resistant gait. Alternatively, it is possible that amyloid has a synergistic effect on other proteins such as tau or αSyn catalyzing protein misfolding,34,–,36 leading to a more aggressive rate of progression in gait disturbance. However, contrary to our hypothesis, we did not see a relationship with total tau or p-tau181. These findings, however, concur with other reports that tau per se is not a primary driver of pathogenesis in PD.8 A combination of plaque formation, αSyn aggregation, and disturbance of neurotransmitter function (e.g., through synaptic rarefication via protein aggregation) is most likely to contribute to mechanisms underpinning gait progression. Age-related white matter burden may also contribute, although our results argue that for this cohort age was not a significant feature. Postmortem follow-up is required to confirm the precise mechanism. It appears that a combination of different pathologic influences mediate gait progression in a discrete manner in PD, emphasizing the need for a multimodal therapeutic approach.

We determined whether gait characteristics were dopa-resistant by modeling gait progression over 3 years from baseline, despite optimal medication. We also identified only those variables that showed significantly greater change compared to controls over the same time period to avoid confounding due to age-associated decline. Controls showed very little change in gait. Participants with PD exhibited significant decline in 3 gait characteristics over and above controls under single task (variability in step time, step length, and step width) and one under dual task (variability of step length). Variability of step time and step length were prominent, in accordance with earlier work. Step time variability in particular is a sensitive marker of incipient pathology.37 Establishing the functional and structural correlates using multimodal brain imaging will help inform the neural basis of these findings. We were also able to discern those gait characteristics that were controlled by levodopa (not reported) (e.g., step length and asymmetry), highlighting specific positive benefits of levodopa medication in early stages.

The effect of single and dual task protocols on results is also worthy of comment. During single-task gait, participants are able to recruit additional attentional resources to maintain gait performance, in contrast to dual-task conditions, which preclude cognitive compensation by distracting attention. Our findings imply that dual task step length variability is mediated through motor circuits, whereas single task step time variability is more likely to be subserved by motor and cognitive networks, as indicated by a (tentative) significant association between the MoCA and step time variability. Brain imaging with amyloid and tau in early PD will help clarify the topographic distribution of pathology driving these changes.

Our findings have interesting clinical implications. CSF Aβ42 is a validated in vivo marker of Aβ accumulation and is implicated in progression of dopa-resistant gait impairments in early PD. Early targeting of Aβ pathology has been proposed as a potential strategy to halt or prevent cognitive decline and dementia in PD.8,9 Therapies to reduce accumulation of amyloid or target its production are under way. We argue that this may also offer the potential to target early gait impairments, and moreover, may provide a global strategy to concurrently target gait and cognitive impairment. Recently, amyloid deposition in the brain and decreased CSF amyloid have also been shown to predict falls in older adults at risk of dementia,37 in support of this. Longer follow-up will determine the relationship with fall risk in our cohort.

Our data also suggest that selective gait characteristics may have a role to play in identifying early PD pathology and specific gait characteristics may be useful markers of progression in disease modification trials. Evidence that motor changes precede cognitive changes is common in older adults38 and has fueled an interest in the role of gait as a clinical biomarker of cognitive decline.6 The shared pathologic mechanisms of gait and cognitive decline support the potential of gait characteristics as clinical biomarkers of cognitive decline in PD14,39 and work is under way investigating this.

Some study limitations should be acknowledged. The population was drawn from an incident PD cohort followed from diagnosis with repeat assessments every 18 months. While misdiagnosis may have contributed, this is unlikely to have had a major effect. Diagnosis followed a stringent process and the flowchart highlights revised diagnosis over the time course of the study, showing that the numbers are low. Dropout may also have confounded our analysis; however, this was low, suggesting it would not exert any undue influence. It is difficult to compare the absolute values of our CSF data with those of others due to the use of different assays across studies. Moreover, we did not have a control cohort with CSF. However, we were able to control for the effects of aging in our gait characteristics, only considering those that changed with respect to controls, and are therefore confident that our findings are PD-specific. Given the difficulty of obtaining CSF, this emphasizes the importance of clinically available biomarkers (such as high step time variability at diagnosis).

Our findings suggest that disturbed Aβ metabolism is a biomarker for dopa-resistant gait impairments in early PD. They also raise interesting questions with respect to therapeutic interventions such as compounds or molecules aimed at reducing amyloid burden to mitigate gait disturbance in early PD and by implication fall risk. Comprehensive reporting of gait characteristics was critical to this study and helped explain the heterogeneity of gait disturbance and therapeutic response. Moreover, selective progression of gait characteristics suggests they may have potential as clinical biomarkers of pathology and disease progression. Finally, the overlap in the pathologic substrates of gait and cognitive decline raises an interesting question as to whether a monotherapy may be able to concurrently target gait and cognitive dysfunction in the future.

AUTHOR CONTRIBUTIONS

Prof. Rochester: PI ICICLE-Gait; responsible for study concept and design, analysis and interpretation, drafted first manuscript. Dr. Galna: data analysis and interpretation, manuscript revision. Dr. Lord and Dr. Yarnall: interpretation and manuscript revision. R. Morris, Dr. Duncan, and Dr. Khoo: data acquisition and manuscript revision. Dr. Mollenhauer: manuscript revision and interpretation. Prof. Burn: PI on ICICLE-PD; manuscript revision.

STUDY FUNDING

Supported by Parkinson's UK (G1507) ICICLE-Gait and ICICLE-PD is supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University and the Lockhart Parkinson's Disease Fund. The research was also supported by NIHR Newcastle CRF Infrastructure funding. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

DISCLOSURE

L. Rochester has received grant support from NIHR, Michael J. Fox Foundation, Wellcome Trust, EU framework 7, MRC, and Parkinson's UK. She has received honoraria from Teva-Lundbeck and USB. B. Galna and S. Lord report no disclosures relevant to the manuscript. A. Yarnall is supported by grants from the Lockhart Parkinson's Disease Research Fund and Michael J. Fox Foundation (MJFF). She has received honoraria from Teva-Lundbeck and sponsorship from UCB, Abbvie, GSK, Teva-Lundbeck, and Genus for attending educational events. R. Morris, G. Duncan, and T. Khoo report no disclosures relevant to the manuscript. B. Mollenhauer has received independent research grants from TEVA-Pharma, Desitin, Boehringer Ingelheim, and GE Healthcare, honoraria for consultancy from Bayer Schering Pharma AG, Roche, AbbVie, TEVA-Pharma, and Biogen, honoraria for presentations from GlaxoSmithKline, Orion Pharma, and TEVA-Pharma, and travel costs from TEVA-Pharma. B.M. is a member of the executive steering committee of the Parkinson Progression Marker Initiative of the Michael J. Fox Foundation for Parkinson's Research and has received grants from the BMBF, EU, Deutsche Parkinson Vereinigung, Michael J. Fox Foundation for Parkinson's Research, and Stifterverband für die deutsche Wissenschaft, and has scientific collaborations with Roche, Bristol Myers Squibb, Ely Lilly, Covance, and Biogen. D. Burn has received grant support from NIHR, Medical Research Council, Wellcome Trust, and Parkinson's UK. He has received honoraria from Profile Pharma and Acadia Pharmaceuticals in the last 12 months. Go to Neurology.org for full disclosures.

ACKNOWLEDGMENT

The authors thank Dadirayi Mhiripiri, Heather Hunter, and Phillip Brown for assistance with data acquisition.

Footnotes

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was funded by Parkinson's UK.

  • Supplemental data at Neurology.org

  • Received August 24, 2016.
  • Accepted in final form December 12, 2016.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

  1. 1.↵
    1. Tanner C,
    2. Goldman S
    . Epidemiology of Parkinson's disease. Neurol Clin 1996;14:317–335.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Lord S,
    2. Galna B,
    3. Yarnall A,
    4. Coleman S,
    5. Burn D,
    6. Rochester L
    . Predicting first fall in newly diagnosed Parkinson's disease: insights for primary prevention in a fall-naive cohort. Mov Disord 2016;31:1829–1836.
    OpenUrl
  3. 3.↵
    1. Bohnen NI,
    2. Frey KA,
    3. Studenski S, et al
    . Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology 2013;81:1611–1616.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Rochester L,
    2. Yarnall AJ,
    3. Baker MR, et al
    . Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain 2012;135:2779–2788.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Henderson EJ,
    2. Lord SR,
    3. Brodie MA, et al
    . Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15:249–258.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Mollenhauer B,
    2. Rochester L,
    3. Chen-Plotkin A,
    4. Brooks D
    . What can biomarkers tell us about cognition in Parkinson's disease? Mov Disord 2014;29:622–633.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Magdalinou N,
    2. Lees AJ,
    3. Zetterberg H
    . Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 2014;85:1065–1075.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Alves G,
    2. Lange J,
    3. Blennow K, et al
    . CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 2014;82:1784–1790.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Siderowf A,
    2. Xie SX,
    3. Hurtig H, et al
    . CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055–1061.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Alves G,
    2. Pedersen KF,
    3. Bloem BR, et al
    . Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:537–543.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Kang JH,
    2. Irwin DJ,
    3. Chen-Plotkin AS, et al
    . Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70:1277–1287.
    OpenUrl
  12. 12.↵
    1. Khoo TK,
    2. Yarnall AJ,
    3. Duncan GW, et al
    . The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013;80:276–281.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Yarnall AJ,
    2. Breen DP,
    3. Duncan GW, et al
    . Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014;82:308–316.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Lord S,
    2. Galna B,
    3. Coleman S,
    4. Yarnall A,
    5. Burn D,
    6. Rochester L
    . Cognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson's disease. Front Aging Neurosci 2014;6:249.
    OpenUrl
  15. 15.↵
    1. Goetz CG,
    2. Tilley BC,
    3. Shaftman SR, et al
    . Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–2170.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Hoehn MM,
    2. Yahr MD
    . Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
    OpenUrlFREE Full Text
  17. 17.↵
    1. Stebbins G,
    2. Goetz CG,
    3. Burn DJ,
    4. Jankovic J,
    5. Tilley BC
    . Postural instability and gait difficulty scores from the MDS-UPDRS. Mov Disord 2011;26:A1077.
    OpenUrl
  18. 18.↵
    1. Tomlinson CL,
    2. Stowe R,
    3. Patel S,
    4. Rick C,
    5. Gray R,
    6. Clarke CE
    . Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649–2653.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Nasreddine ZS,
    2. Phillips NA,
    3. Bedirian V, et al
    . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–699.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Wechsler D
    . WAIS-III: Administration and Scoring Manual, 3rd ed. San Antonio: Psychological Corporation; 1997.
  21. 21.↵
    1. Rochester L,
    2. Galna B,
    3. Lord S,
    4. Burn D
    . The nature of dual-task interference during gait in incident Parkinson's disease. Neuroscience 2014;265:83–94.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Galna B,
    2. Lord S,
    3. Rochester L
    . Is gait variability reliable in older adults and Parkinson's disease? Towards an optimal testing protocol. Gait Posture 2013;37:580–585.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Lord S,
    2. Galna B,
    3. Verghese J,
    4. Coleman S,
    5. Burn D,
    6. Rochester L
    . Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. J Gerontol A Biol Sci Med Sci 2013;68:820–827.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Lord S,
    2. Galna B,
    3. Rochester L
    . Moving forward on gait measurement: toward a more refined approach. Mov Disord 2013;28:1534–1543.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Galna B,
    2. Lord S,
    3. Burn DJ,
    4. Rochester L
    . Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype. Mov Disord 2015;30:359–367.
    OpenUrl
  26. 26.↵
    1. Mollenhauer B,
    2. Bibl M,
    3. Wiltfang J, et al
    . Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 2006;44:192–195.
    OpenUrlPubMed
  27. 27.↵
    1. Kruse N,
    2. Mollenhauer B
    . Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human alpha-Synuclein in cerebrospinal fluid. J Immunol Methods 2015;426:70–75.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Bates D,
    2. Maechler M,
    3. Bolker B,
    4. Walker S
    . lme4: linear mixed-effects models using Eigen and S4 [computer program]. R package version 11-8. Available at: CRANR-projectorg/package=lme4. Accessed April 21, 2015.
  29. 29.↵
    R: a language and environment for statistical computing [computer program]. Available at: R-project.org. Accessed April 21, 2015.
  30. 30.↵
    1. Muller ML,
    2. Frey KA,
    3. Petrou M, et al
    . β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord 2013;28:296–301.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Simuni T,
    2. Caspell-Garcia C,
    3. Coffey C, et al
    . How stable are Parkinson's disease subtypes in de novo patients: analysis of the PPMI cohort? Parkinsonism Relat Disord 2016;28:62–67.
    OpenUrl
  32. 32.↵
    1. Fagan A,
    2. Mintun M,
    3. Mach R, et al
    . Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann Neurol 2006;59:512–519.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Lim H,
    2. Nebes R,
    3. Snitz B, et al
    . Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain 2014;137:3327–3338.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Pletnikova O,
    2. West N,
    3. Lee M, et al
    . Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005;26:1183–1192.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Lashley T,
    2. Holton JL,
    3. Gray E, et al
    . Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008;115:417–425.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Clinton L,
    2. Blurton-Jones M,
    3. Myczek K,
    4. Trojanowski J,
    5. LaFerla F
    . Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010;30:7281–7289.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Stark SL,
    2. Roe CM,
    3. Grant EA, et al
    . Preclinical Alzheimer disease and risk of falls. Neurology 2013;81:437–443.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Verghese J,
    2. Wang C,
    3. Lipton RB,
    4. Holtzer R,
    5. Xue X
    . Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry 2007;78:929–935.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Morris R,
    2. Lord S,
    3. Bunce J,
    4. Burn D,
    5. Rochester L
    . Gait and cognition: mapping the global and discrete relationships in ageing and neurodegenerative disease. Neurosci Biobehav Rev 2016;64:326–345.
    OpenUrl
View Abstract

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me